Nordisk and Sanofi log double-digit revenue growth in insulin pens

Multinational drug majors Novo Nordisk and Sanofi, leaders in India's insulin pens market, have both seen double-digit revenue growth in this segment over a year, helped by price increases.

This happened despite volume growth having slowed. Data from market research entity AIOCD AWACS showed this growth in the segment (moving annual turnover or MAT unit sales growth in August) was only 0.2 per cent. Around 6.98 million insulin pens were sold; it was 6.97 mn in the year-before period (when volumes grew 4.8 per cent annually).

However, while volume growth was flat, value growth was 9.6 per cent for the segment. And,